Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Scinai Immunotherapeutics Ltd./ EFFECT

Notice of Effectiveness · EFFECT

Scinai Immunotherapeutics Ltd.

Notice of Effectiveness

Filed Oct 5, 2026Accepted Oct 6, 2026, 12:15 AM EDTFiling CIK 1611747Accession 9999999995-26-003155
View company →Permanent SEC source ↗
Share

Structured filing — EFFECT

primary_doc.xml

Open full document ↗

Notice details

Submission type
EFFECT
Act
33

Effectiveness

Effective date
2026-10-05
Effective time (as filed)
09:00:00
Form
F-1

Registrant 1

Registrant
Scinai Immunotherapeutics Ltd.
Registrant CIK
0001611747
File number
333-299112

Company context

We are a biopharmaceutical company focused on the development of innovative immunology therapies and the operation of a contract development and manufacturing organization. We are advancing a pipeline of therapeutic candidates licensed from the Max Planck Society. We also own Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), providing development and manufacturing services to biotechnology and pharmaceutical companies.

Current securities

SCNINASDAQ · ADR · Current
Historical securities (1)
BVXVWNASDAQ · WARRANT · Historical · closed May 14, 2020

Recent company filings

  1. 6-K filingOct 15, 2026
  2. 6-K filingOct 13, 2026
  3. F-1 filingSep 24, 2026
  4. 6-K filingSep 21, 2026
  5. 6-K filingSep 8, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.